Support

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Sunday, 08 August 2021 11:19

Eva Domenjo

Written by
Sunday, 08 August 2021 11:19

Miguel Angel Molina

Written by
Sunday, 08 August 2021 11:19

Andreas Meyerhans

Written by
Sunday, 08 August 2021 11:19

Teresa Moran

Written by
Sunday, 08 August 2021 11:19

Daniel Benitez

Written by
Sunday, 08 August 2021 11:19

Benjamin Drapkin

Written by
I am a medical oncologist at UT Southwestern specializing in the care of lung cancer patients, with a focus on small cell lung cancer (SCLC). My laboratory, located in the Hamon Center for Therapeutic Oncology, focuses on translational research in SCLC and other aggressive neuroendocrine tumors. We leverage a large panel of patient-derived xenograft (PDX) models that closely recapitulate the clinical features of their corresponding patients to discover new targets and develop new therapies for this deadly disease. We have three current areas of focus: (1) strategies to overcome or circumvent chemotherapy cross-resistance, which renders relapsed SCLC refractory to further care, (2) elucidation of the mechanism by which lineage transdifferentiation between lung adenocarcinoma and SCLC occurs, and (3) approaches to target loss of the retinoblastoma tumor suppressor (RB1), a genomic hallmark of SCLC, by synthetic lethality.
Sunday, 08 August 2021 11:19

Anish Thomas

Written by
Anish Thomas is a clinical researcher and thoracic oncologist. The goals of his research program are: 1) to develop more effective therapies for patients with SCLC by targeting DNA replication, repair, and chromatin remodeling, and 2) genomic characterization of SCLCs to better understand the basis of treatment response and resistance. Work from his group has revealed replication stress as a transformative vulnerability of SCLCs characterized by high neuroendocrine differentiation, targetable by ATR inhibition (Cancer Cell 2021 PMID: 33848478; J Clin Oncol 2018; PMID: 29252124), provided novel insights into the transcriptomic features that render low neuroendocrine SCLC more sensitive to immunotherapy (Nat Commun, PMID: 34162872), and discovered a novel SCLC subset defined by the germline genotype and improved responses to DNA repair targeted drugs (Sci Trans Med 2021; PMID: 33504652).
Sunday, 08 August 2021 11:19

Ufuk Yılmaz

Written by
Sunday, 08 August 2021 11:19

Ahmet Yanarateş

Written by
Page 206 of 371